缬沙坦联合灯盏花素治疗早期糖尿病肾病的疗效观察

Breviscapine Valsartan Combined Treatment of Early Diabetic Nephropathy

目的:观察缬沙坦联合灯盏花素治疗早期糖尿病肾病的疗效。方法:68例糖尿病肾病患者采用随机平行分组对照方法分为两组,对照组34例,给予缬沙坦80mg/天;治疗组34例,在给予缬沙坦80mg/天的基础上给予灯盏花素50mg静脉滴注,每日1次;疗程均为4周,观察治疗前后24h尿蛋白定量(UEA)、尿白蛋白排泄率(UAER)、血肌酐(SCr)、空腹血糖(FBG)、血清(CRP)。结果:两组治疗后24h尿蛋白定量、尿白蛋白排泄率均明显下降(P<0.05或P<0.01),且组间比较有明显差异(P<0.01)。疗程结束后治疗组血清CRP降低显著(P<0.01)。对照组降低不明显(P>0.05),组间差异有统计学(P<0.01)意义,两组的血肌酐(SCr)、空腹血糖治疗前后及组间比较差异无显著性(P>0.05)。结论:缬沙坦与灯盏花素联合应用可减少尿白蛋白,降低血清CRP水平,对早期糖尿病肾病的治疗有协同作用,值得推广应用。

Objective：To observe the effect of valsartan combined breviscapine treatment of early diabetic nephropathy. Methods：68 patients with diabetic nephropathy in patients randomized parallel group comparison methods were divided into two groups,control group 34 patients given valsartan 80mg / d; treatment group 34 cases,the granting of valsartan 80mg / d based on the given Breviscapine 50mg intravenous infusion,daily one time; course of treatment for 4 weeks was observed before and after treatment a 24-hour urinary protein （UEA）,urinary albumin excretion rate （UAER）,serum creatinine （SCr）,fasting blood glucose （FBG）,serum （CRP）. Results：group 2 after treatment a 24-hour urinary protein,urinary albumin excretion rate decreased significantly （P〈0.05 or P〈0.01）,and the significant difference between the two groups （P〈0.01）. Treatment after the end of treatment to reduce serum levels of CRP significantly （P〈0.01）. The control group not significantly lower （P〈0.05）,difference between the two groups was statistically （P〈0.01） significance,two groups serum creatinine （SCr）,fasting blood glucose before and after treatment and no difference between the two groups was significant （P〈0.05）. Conclusions：Valsartan in combination with Breviscapine can reduce urinary albumin and lower serum CRP levels,early treatment of diabetic nephropathy synergy is worth popularizing.